MA38454A1 - Inhibiteurs de protéines kinases - Google Patents
Inhibiteurs de protéines kinasesInfo
- Publication number
- MA38454A1 MA38454A1 MA38454A MA38454A MA38454A1 MA 38454 A1 MA38454 A1 MA 38454A1 MA 38454 A MA38454 A MA 38454A MA 38454 A MA38454 A MA 38454A MA 38454 A1 MA38454 A1 MA 38454A1
- Authority
- MA
- Morocco
- Prior art keywords
- protein kinase
- kinase inhibitors
- useful
- formula
- fgfr
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un composé de formule (i), dans laquelle r1 à r5, a, b, z, z1 et z2 étant tels que définis dans les revendications, et des sels pharmaceutiquement acceptables de celui-ci. Les composés de formule (i) selon l'invention sont utiles en tant qu'inhibiteurs de fgfr et sont utiles dans le traitement d'une affection où l'inhibition de la fgfr kinase est souhaitée, telle que le cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN382KO2013 | 2013-04-04 | ||
| PCT/FI2014/000003 WO2014162039A1 (fr) | 2013-04-04 | 2014-04-03 | Inhibiteurs de protéines kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38454A1 true MA38454A1 (fr) | 2018-02-28 |
| MA38454B1 MA38454B1 (fr) | 2018-11-30 |
Family
ID=50685938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38454A MA38454B1 (fr) | 2013-04-04 | 2014-04-03 | Inhibiteurs de protéines kinases |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20160031855A1 (fr) |
| EP (1) | EP2981533B1 (fr) |
| JP (1) | JP6356782B2 (fr) |
| KR (1) | KR20150138383A (fr) |
| CN (1) | CN105073733B (fr) |
| AR (1) | AR095781A1 (fr) |
| AU (1) | AU2014246961B2 (fr) |
| BR (1) | BR112015025413A2 (fr) |
| CA (1) | CA2907855A1 (fr) |
| CL (1) | CL2015002932A1 (fr) |
| CY (1) | CY1120306T1 (fr) |
| DK (1) | DK2981533T3 (fr) |
| EA (1) | EA031076B1 (fr) |
| ES (1) | ES2658183T3 (fr) |
| HR (1) | HRP20180382T1 (fr) |
| HU (1) | HUE036692T2 (fr) |
| LT (1) | LT2981533T (fr) |
| MA (1) | MA38454B1 (fr) |
| MX (1) | MX2015013776A (fr) |
| MY (1) | MY184528A (fr) |
| NO (1) | NO2981533T3 (fr) |
| NZ (1) | NZ713410A (fr) |
| PE (1) | PE20160115A1 (fr) |
| PH (1) | PH12015502284B1 (fr) |
| PL (1) | PL2981533T3 (fr) |
| PT (1) | PT2981533T (fr) |
| RS (1) | RS56942B1 (fr) |
| SA (1) | SA515361260B1 (fr) |
| SG (1) | SG11201508125XA (fr) |
| SI (1) | SI2981533T1 (fr) |
| TW (1) | TWI628176B (fr) |
| UA (1) | UA115176C2 (fr) |
| WO (1) | WO2014162039A1 (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| PE20190736A1 (es) | 2012-06-13 | 2019-05-23 | Incyte Holdings Corp | Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr) |
| WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| ES2914072T3 (es) | 2014-08-18 | 2022-06-07 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monocíclico y su cristal |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3275442B1 (fr) | 2015-03-25 | 2021-07-28 | National Cancer Center | Agent thérapeutique contre le cancer du canal cholédoque |
| RU2730503C2 (ru) | 2015-12-17 | 2020-08-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения рака молочной железы |
| US10487863B2 (en) * | 2017-02-17 | 2019-11-26 | Ford Global Technologies, Llc | Castellated joint for improved adhesive coverage when using mechanical fixings and adhesive in one joint |
| CN109963854B (zh) | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3777860A4 (fr) | 2018-03-28 | 2021-12-15 | Eisai R&D Management Co., Ltd. | Agent thérapeutique pour le carcinome hépatocellulaire |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| SI3788047T1 (sl) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Trdne oblike inhibitorja fgfr in postopki priprave le-teh |
| WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3141424C (fr) * | 2019-06-14 | 2023-11-07 | Zhengxia CHEN | Compose cyclique fusionne en tant qu'inhibiteur double de fgfr et vegfr |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7300057B2 (ja) * | 2019-07-26 | 2023-06-28 | シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド | Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としてのピリジン誘導体 |
| WO2021067374A1 (fr) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021113462A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Dérivés d'un inhibiteur de fgfr |
| EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
| WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| CN116783192B (zh) * | 2021-01-26 | 2025-10-31 | 盛世泰科生物医药技术(苏州)股份有限公司 | 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法 |
| WO2022203399A1 (fr) * | 2021-03-26 | 2022-09-29 | 주식회사 스탠다임 | Antagoniste du récepteur a2a de l'adénosine et son utilisation |
| WO2022221170A1 (fr) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4 |
| WO2022261159A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
| WO2022261160A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1194152A4 (fr) * | 1999-06-30 | 2002-11-06 | Merck & Co Inc | Composes inhibiteurs de la kinase src |
| US6329380B1 (en) * | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| US7521448B2 (en) * | 2003-08-21 | 2009-04-21 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-Kit inhibitors |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| HRP20151398T1 (hr) * | 2006-12-22 | 2016-02-12 | Astex Therapeutics Limited | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze |
| CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| GB0906472D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CN102216300B (zh) * | 2009-09-30 | 2014-10-22 | 贝达药业股份有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| UA111382C2 (uk) * | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
-
2014
- 2014-04-02 TW TW103112259A patent/TWI628176B/zh not_active IP Right Cessation
- 2014-04-03 CN CN201480019409.6A patent/CN105073733B/zh not_active Expired - Fee Related
- 2014-04-03 CA CA2907855A patent/CA2907855A1/fr not_active Abandoned
- 2014-04-03 ES ES14722686.4T patent/ES2658183T3/es active Active
- 2014-04-03 SI SI201430589T patent/SI2981533T1/en unknown
- 2014-04-03 MA MA38454A patent/MA38454B1/fr unknown
- 2014-04-03 HU HUE14722686A patent/HUE036692T2/hu unknown
- 2014-04-03 EA EA201591913A patent/EA031076B1/ru not_active IP Right Cessation
- 2014-04-03 PL PL14722686T patent/PL2981533T3/pl unknown
- 2014-04-03 NO NO14722686A patent/NO2981533T3/no unknown
- 2014-04-03 SG SG11201508125XA patent/SG11201508125XA/en unknown
- 2014-04-03 US US14/782,020 patent/US20160031855A1/en not_active Abandoned
- 2014-04-03 NZ NZ713410A patent/NZ713410A/en not_active IP Right Cessation
- 2014-04-03 KR KR1020157031629A patent/KR20150138383A/ko not_active Withdrawn
- 2014-04-03 PE PE2015002104A patent/PE20160115A1/es not_active Application Discontinuation
- 2014-04-03 PT PT147226864T patent/PT2981533T/pt unknown
- 2014-04-03 BR BR112015025413A patent/BR112015025413A2/pt not_active Application Discontinuation
- 2014-04-03 DK DK14722686.4T patent/DK2981533T3/en active
- 2014-04-03 RS RS20180257A patent/RS56942B1/sr unknown
- 2014-04-03 UA UAA201510726A patent/UA115176C2/uk unknown
- 2014-04-03 HR HRP20180382TT patent/HRP20180382T1/hr unknown
- 2014-04-03 EP EP14722686.4A patent/EP2981533B1/fr active Active
- 2014-04-03 LT LTEP14722686.4T patent/LT2981533T/lt unknown
- 2014-04-03 AU AU2014246961A patent/AU2014246961B2/en not_active Ceased
- 2014-04-03 MX MX2015013776A patent/MX2015013776A/es unknown
- 2014-04-03 MY MYPI2015703505A patent/MY184528A/en unknown
- 2014-04-03 JP JP2016505869A patent/JP6356782B2/ja not_active Expired - Fee Related
- 2014-04-03 WO PCT/FI2014/000003 patent/WO2014162039A1/fr not_active Ceased
- 2014-04-04 AR ARP140101492A patent/AR095781A1/es unknown
-
2015
- 2015-10-01 PH PH12015502284A patent/PH12015502284B1/en unknown
- 2015-10-02 CL CL2015002932A patent/CL2015002932A1/es unknown
- 2015-10-04 SA SA515361260A patent/SA515361260B1/ar unknown
-
2018
- 2018-02-21 CY CY20181100204T patent/CY1120306T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38454A1 (fr) | Inhibiteurs de protéines kinases | |
| MA54327B1 (fr) | Inhibiteurs de kras g12c | |
| MA46337A (fr) | Composé de pyridine | |
| MA44820A1 (fr) | Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase | |
| SA521421205B1 (ar) | مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| MA52948B1 (fr) | Composés | |
| MA44721B1 (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| MA42341A1 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| MA38884A1 (fr) | Composé de triazolopyridine, compositions et procédés d'utilisation associés | |
| MA39048A1 (fr) | Nouveaux inhibiteurs de la dgat2 | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| ZA202207449B (en) | Selective cdk4/6 inhibitor cancer therapeutics | |
| EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
| BR112018010812A2 (pt) | compostos de 1,3,4-tiadiazol e uso dos mesmos no tratamento do câncer | |
| MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
| CA3128282C (fr) | Composes de vinylbenzamide comme immunomodulateur de pd-l1 | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
| MA39019A1 (fr) | Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside |